The extended trading session last Friday showed a notable 7.33% increase in SeaStar Medical Holding Corporation (NASDAQ: ICU) shares, which ended the day at $3.57. This spike came after the company’s novel Selective Cytopheretic Device (SCD) pediatric therapeutic device, QUELIMMUNE, was presented at a major nephrology convention with encouraging new results.
Presentation at 2024 Kidney Week
Last week, during the American Society of Nephrology’s (ASN) Kidney Week 2024 in San Diego, SeaStar Medical (ICU) made a significant announcement. Data demonstrating QUELIMMUNE’s cost-saving potential in treating critically sick pediatric patients with acute kidney damage (AKI) linked to sepsis was initially provided by the firm. According to this ground-breaking research, healthcare organizations that use QUELIMMUNE as part of their treatment arsenal stand to gain significantly financially.
QUELIMMUNE: Cost Savings and Clinical Benefits
The analysis, titled “Cost Impact of An Immunomodulatory Selective Cytopheretic Device in Pediatrics (SCD-PED) in AKI due to Sepsis (AKI-S)”, revealed substantial cost reductions when using QUELIMMUNE. According to data from the Kids’ Inpatient Database (KID), the average cost of hospitalization for pediatric patients with AKI requiring continuous renal replacement therapy (CRRT) was $461,736 per hospitalization.
The findings showed that treatment with QUELIMMUNE resulted in projected savings of approximately $30,000 per hospitalization. These savings were primarily driven by lower mortality rates and shorter hospital stays, underscoring the device’s clinical and operational efficiency.
Broader Implications for Hospitals
Importantly, these results indicate a strong potential for widespread adoption of QUELIMMUNE across hospital systems, particularly in managing pediatric AKI linked to sepsis. The Centers for Medicare & Medicaid Services (CMS) has already recognized the critical nature of sepsis through the SEP-1 protocol, further emphasizing the importance of innovative solutions like QUELIMMUNE in improving outcomes and reducing costs.
SeaStar Medical’s Strong Presence at Kidney Week
SeaStar Medical (ICU) continues to build its reputation at Kidney Week 2024 with the presentation of four posters. In addition to the QUELIMMUNE cost analysis, another poster presented by the company focuses on the reduction of hyperinflammatory markers in patients with AKI, highlighting further potential therapeutic benefits of its products.
